Desvenlafaxine (Pristiq)
Serotonin-norepinephrine reuptake inhibitor (SNRI) / Antidepressant
Desvenlafaxine (Pristiq)
Forms and strengths
Form: TabletStrength: 50 mg, 100 mg
References
Indication
- Desvenlafaxine is indicated for the symptomatic relief of major depressive disorder in adults.
- Desvenlafaxine has not been shown to work better than placebo for depression in children or teenagers and is not approved for use in patients under 18.
Pregnancy
- Desvenlafaxine has not been established as safe in human pregnancy, and it crosses the placenta, so it should be used during pregnancy only if the potential benefit justifies the potential risk.
- Use late in the third trimester has been linked to complications in newborns, including breathing difficulties, feeding problems, low blood sugar, and jitteriness, so the risks and benefits should be weighed carefully if treatment continues close to delivery.
- Exposure to desvenlafaxine in mid-to-late pregnancy may raise the risk of preeclampsia, and exposure near delivery may raise the risk of heavy bleeding after childbirth.
Breastfeeding
- Desvenlafaxine passes into breast milk, and its effects on a nursing infant are not established, so it should only be used while breastfeeding if the expected benefit outweighs the possible risk.
Geriatrics
- Older adults did not show overall differences in safety or effectiveness compared with younger adults taking desvenlafaxine.
- Elderly patients had a higher rate of increased systolic blood pressure and a higher rate of low blood pressure on standing (orthostatic hypotension) than younger adults, so blood pressure should be monitored closely.
- Reduced kidney clearance in older adults should be considered when determining dose.
Pediatrics
- Desvenlafaxine is not approved for use in children or adolescents under 18 years of age.
- Two placebo-controlled studies in children and teenagers with major depressive disorder failed to show that desvenlafaxine worked better than placebo.
- Children treated with desvenlafaxine experienced more weight loss and upper abdominal pain than those on placebo.
Dosage & Administration
- The recommended starting dose of desvenlafaxine for adults is 50 mg once daily, with or without food.
- Doses above 50 mg per day have not shown additional benefit in clinical studies, but if a physician decides a higher dose is warranted, the maximum recommended dose is 100 mg per day.
- Patients with severe kidney impairment or end-stage renal disease should take 50 mg every other day; supplemental doses should not be given after dialysis.
- No dose adjustment is needed for liver impairment or based on age alone, though reduced kidney clearance should be considered in older adults.
- Desvenlafaxine tablets must be swallowed whole with liquid and never chewed, divided, or crushed, since they are designed to release the drug at a controlled rate.
- If a dose is missed, take it as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped; never double up.
- Desvenlafaxine should never be stopped abruptly; the dose should be tapered gradually under medical supervision to avoid discontinuation symptoms.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose experience with desvenlafaxine in humans is limited; reported symptoms after high-dose ingestion include headache, vomiting, agitation, dizziness, nausea, constipation, diarrhea, dry mouth, tingling sensations, and a fast heart rate.
- Because desvenlafaxine is the main active form of venlafaxine, more severe overdose effects reported with venlafaxine may also apply, including a very fast heart rate, seizures, changes in consciousness up to coma, dilated pupils, heart rhythm changes on ECG, low blood pressure, muscle breakdown, and liver damage.
- Overdose has more often been reported when desvenlafaxine or venlafaxine was combined with alcohol or other drugs, including fatal cases.
- There is no specific antidote; treatment is supportive, with attention to airway, breathing, and heart rhythm, and activated charcoal may be given if the patient presents soon after ingestion.
- Dialysis is unlikely to remove a meaningful amount of desvenlafaxine from the body because of how the drug distributes into body tissues.
Common side effects
- Nausea is a common side effect of desvenlafaxine, especially when starting treatment.
- Headache may occur.
- Dry mouth may occur.
- Dizziness may occur.
- Insomnia (difficulty sleeping) may occur.
- Increased sweating (hyperhidrosis) may occur.
- Constipation may occur.
- Diarrhea may occur.
- Drowsiness (somnolence) may occur.
- Fatigue may occur.
- Decreased appetite may occur.
- Vomiting may occur.
- Increased blood pressure may occur.
- Erectile dysfunction may occur in men taking desvenlafaxine.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Desvenlafaxine carries an increased risk of suicidal thinking and behaviour, particularly in the first weeks of treatment or after a dose change; patients of all ages should be monitored closely for worsening mood or new agitation.
- Serotonin syndrome, a potentially life-threatening reaction marked by agitation, rapid heartbeat, muscle twitching, sweating, high fever, and confusion, can occur, especially when combined with other serotonergic drugs.
- Elevated blood pressure, including hypertensive crisis, has been reported and requires regular blood pressure monitoring during treatment.
- Abnormal bleeding, ranging from bruising and nosebleeds to serious gastrointestinal or other hemorrhage, may occur, especially when combined with NSAIDs, aspirin, or blood thinners.
- Angle-closure glaucoma can be triggered in patients with narrow ocular angles; sudden eye pain, vision changes, or eye redness or swelling need immediate medical attention.
- Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely.
- Mania or hypomania may be triggered, particularly in patients with an underlying or family history of bipolar disorder.
- Seizures have been reported.
- Discontinuation symptoms such as irritability, dizziness, sensory disturbances, anxiety, and headache can occur if the drug is stopped abruptly, and can be severe or prolonged in some patients.
- Interstitial lung disease and eosinophilic pneumonia have been reported rarely, presenting with progressive shortness of breath, cough, or chest discomfort.
- Rare cases of stress cardiomyopathy (Takotsubo cardiomyopathy) have been reported.
- Seek urgent medical attention for chest pain, fainting, severe allergic reactions, signs of serotonin syndrome, unusual bleeding, or new or worsening suicidal thoughts.
Use with caution
- Use with caution in patients with cardiovascular disease, since desvenlafaxine can raise blood pressure and heart rate.
- Use with caution in patients with a history of bleeding disorders or those taking other drugs that affect bleeding, such as NSAIDs, aspirin, or anticoagulants.
- Use with caution in patients with a seizure disorder.
- Use with caution in patients with narrow-angle glaucoma or other eye conditions affecting the pupil.
- Use with caution in patients with a personal or family history of mania, hypomania, or bipolar disorder.
- Use with caution in patients with pre-existing gastrointestinal narrowing, since the tablet shell does not readily change shape as it passes through the gut.
- Use with caution in elderly patients, who may be more sensitive to blood pressure and heart rate changes and have reduced kidney clearance.
- Use with caution in patients with risk factors for bone fracture, since SNRIs have been linked to an increased fracture risk.
- Use with caution when driving or operating machinery until the effect of desvenlafaxine on alertness and coordination is known.
Contraindications
- Contraindicated in patients taking, or who have taken within the past 14 days, a monoamine oxidase inhibitor (MAOI), due to the risk of serious or fatal serotonin toxicity.
- Contraindicated in patients hypersensitive to desvenlafaxine, venlafaxine, or any ingredient in the formulation.
Drug interactions
- Concurrent use with MAOIs is contraindicated and requires a washout period of at least 14 days before starting desvenlafaxine, and at least 7 days after stopping desvenlafaxine before starting an MAOI.
- Combining desvenlafaxine with other serotonergic drugs, including SSRIs, other SNRIs, triptans such as zolmitriptan or sumatriptan, lithium, tramadol, fentanyl, tryptophan supplements, or St. John's Wort, increases the risk of serotonin syndrome.
- Concomitant use with venlafaxine-containing products should be avoided, since desvenlafaxine is the main active form of venlafaxine and combined use leads to additive exposure.
- Combining desvenlafaxine with NSAIDs, aspirin, warfarin, or other anticoagulants may increase the risk of bleeding.
- Ketoconazole and other potent CYP3A4 inhibitors can increase desvenlafaxine blood levels.
- Desvenlafaxine may increase blood levels of drugs metabolized by CYP2D6, such as desipramine, requiring caution when combined.
- Combining desvenlafaxine with other central nervous system-active drugs may have additive sedative or psychomotor effects.
- Desvenlafaxine can cause false-positive urine drug screening results for phencyclidine (PCP) and amphetamines.
Food interactions
- Desvenlafaxine can be taken with or without food; a high-fat meal does not meaningfully change how much of the drug is absorbed.
Time of administration
- Desvenlafaxine is taken once daily, with or without food, at approximately the same time each day to keep blood levels steady.
Storage
- Store desvenlafaxine tablets at room temperature between 15°C and 30°C.
Patient take-away
- Desvenlafaxine (Pristiq) is an antidepressant that may take several weeks to show its full effect, so it should be taken consistently even if improvement is not felt right away.
- Never stop desvenlafaxine suddenly; work with a pharmacist or doctor to taper the dose gradually to avoid discontinuation symptoms.
- Report any new or worsening mood changes, agitation, or thoughts of self-harm to a healthcare professional right away, especially when starting treatment or changing the dose.